Bavarian Nordic to acquire Vivotif and Vaxchora travel vaccines from Emergent BioSolutions
Bavarian Nordic A/S will acquire two oral vaccines from Emergent BioSolutions for a total consideration of up to $380 million, to strengthen its position in the travel vaccines space. The acquisition is expected to help Bavarian Nordic expand its US commercial sales, marketing, and distribution network, as well as increased scale in additional European markets. […]